Inquiry
Form loading...

Rosuvastatin tert butyl ester 355806-00-7

IUPAC Name: tert-butyl (E,3R,5S)-7-[4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-propan-2-ylpyrimidin-5-yl]-3,5-dihydroxyhept-6-enoate
CAS: 355806-00-7
Molecular Weight: 537.66
Molecular Formula: C26H36FN3O6S
Quality Standard: In House

    Product Specification

    Appearance:

    white to yellow power

    Identification:

    HPLC: The retention time of test substance is similar toreference substance

    Loss on drying

    ≤0.5%

    Residue on ignition:

    ≤0.08%

    Related Substance:

    Acid impurity≤1.0%、RSL≤1.0%、RSM≤0.5%、Desfluoro ofRS-11≤0.10%、RS-11D1≤0.15%、Cis-isomer of RS-11≤0.10%、RS-10≤0.10%、Individual unspecified impurity≤0.10%、Total impurities≤0.20%

    Enantiomer:

    ≤0.15

    Assay:

     

    98.0%~102.0%(Calculated on the dried basis )

    description1

    PRODUCT DESCRIPTION

    One metabolite of rosuvastatin is rosuvastatin tert-Butyl Ester. Rosuvastatin, sometimes referred to as an antilipemic agent, is a member of the statin drug class, which is mostly prescribed to treat dyslipidemia, which includes elevated cholesterol and associated disorders. When used in conjunction with a nutritious diet and regular exercise, it works by inhibiting the enzyme that the body uses to produce cholesterol. This effectively lowers blood levels of triglycerides and total cholesterol while increasing levels of HDL cholesterol, the good kind of cholesterol. Additionally, it is used to treat individuals with specific hereditary cholesterol abnormalities. 

    Moreover, rosuvastatin is helpful in preventing cardiovascular illnesses since excessive cholesterol is linked to angiocardiopathy. It is used to lower the risk of heart attacks, strokes, and angioplasty in those with at least two cardiovascular disease risk factors.

    British company AstraZeneca successfully developed rosuvastatin, an HMG-CoA reductase inhibitor that treats hyperlipidemia. Suitable for treating a range of lipid abnormalities, such as simple hypertriglyceridemia, mixed lipid abnormalities, primary hypercholesterolemia, and hyperlipidemia-complicated senile coronary heart disease. Right now, rosuvastatin is the statin that has the most potent and all-encompassing lipid-lowering effect available. It outperforms the industry leader atorvastatin in terms of lowering LDL cholesterol and improving HDL function, and it also has better tolerability, fewer side effects, and distinct pharmacokinetic effects.